Cologuard (Exact Sciences Corp.)
HAYES, Inc
Record ID 32018000082
English
Authors' recommendations:
Fecal-based colorectal cancer (CRC) screening tests have been used to detect hemoglobin, a measure of fecal occult blood (FOB), in stool, which is a nonspecific sign of CRC. In general, fecalbased CRC screening is a tool to improve CRC detection without the inconvenience (i.e., bowel preparation and time commitment) of screening colonoscopy or other invasive methods. Fecal-based assessment can also include the analysis of DNA found in the stool, detecting alterations that may occur during CRC carcinogenesis from cells that are shed into the stool. Stool-based tests using DNA biomarkers plus FOB screening are presumed to detect more CRCs than FOB alone. This report reviews the Cologuard (Exact Sciences Corp.) combination cancer screening test.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=77266
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Biomarkers
- Calcium Hydroxide
- Carcinogenesis
- Colonoscopy
- Colorectal Neoplasms
- DNA
- Early Detection of Cancer
- Guaiac
- Hemoglobin A
- Humans
- Occult Blood
- Zinc Oxide
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.